551 related articles for article (PubMed ID: 36614011)
1. What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances.
Watanabe K; Sato E; Mishima E; Miyazaki M; Tanaka T
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614011
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression.
Wang N; Zhang C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542060
[TBL] [Abstract][Full Text] [Related]
3. Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease.
Bayne S; LeFevre J; Olstinske K; Ravindran S; Munusamy S
Adv Biol (Weinh); 2024 Mar; 8(3):e2300496. PubMed ID: 38065929
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next?
Salman L; Martinez L; Faddoul G; Manning C; Ali K; Salman M; Vazquez-Padron R
Kidney360; 2023 Jun; 4(6):e851-e860. PubMed ID: 37055910
[TBL] [Abstract][Full Text] [Related]
6. Treatment of diabetic kidney disease. A network meta-analysis.
Büttner F; Barbosa CV; Lang H; Tian Z; Melk A; Schmidt BMW
PLoS One; 2023; 18(11):e0293183. PubMed ID: 37917640
[TBL] [Abstract][Full Text] [Related]
7. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
Bell DSH; Jerkins T
Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874
[TBL] [Abstract][Full Text] [Related]
8. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
Al Dhaybi O; Bakris GL
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():69-76. PubMed ID: 32267074
[TBL] [Abstract][Full Text] [Related]
9. Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!
Malek V; Suryavanshi SV; Sharma N; Kulkarni YA; Mulay SR; Gaikwad AB
Rev Physiol Biochem Pharmacol; 2021; 179():31-71. PubMed ID: 32979084
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
Yao L; Liang X; Wang P
Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
[TBL] [Abstract][Full Text] [Related]
11. Slowing the Progression of Diabetic Kidney Disease.
Blazek O; Bakris GL
Cells; 2023 Jul; 12(15):. PubMed ID: 37566054
[TBL] [Abstract][Full Text] [Related]
12. Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists.
Mende CW; Samarakoon R; Higgins PJ
Am J Nephrol; 2023; 54(1-2):50-61. PubMed ID: 36682353
[TBL] [Abstract][Full Text] [Related]
13. Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.
Mazzieri A; Porcellati F; Timio F; Reboldi G
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612779
[TBL] [Abstract][Full Text] [Related]
14. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy.
Sato A; Nishimoto M
Hypertens Res; 2022 Aug; 45(8):1310-1321. PubMed ID: 35726084
[TBL] [Abstract][Full Text] [Related]
15. Update on role of direct renin inhibitor in diabetic kidney disease.
Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
Gohda T; Murakoshi M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
[TBL] [Abstract][Full Text] [Related]
17. Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
Chung EYM; Badve SV; Heerspink HJL; Wong MG
Nephrology (Carlton); 2023 Feb; 28(2):97-108. PubMed ID: 36350038
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease: A systematic review and network meta-analysis.
Zhang L; Miao R; Yu T; Wei R; Tian F; Huang Y; Tong X; Zhao L
Pharmacol Res; 2022 Mar; 177():106111. PubMed ID: 35183713
[TBL] [Abstract][Full Text] [Related]
19. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
20. Targeting inflammation to treat diabetic kidney disease: the road to 2030.
Rayego-Mateos S; Rodrigues-Diez RR; Fernandez-Fernandez B; Mora-Fernández C; Marchant V; Donate-Correa J; Navarro-González JF; Ortiz A; Ruiz-Ortega M
Kidney Int; 2023 Feb; 103(2):282-296. PubMed ID: 36470394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
